Cargando…
In silico biatrial fibrosis ablation improves atrial fibrillation outcome
FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Medical Research Council Fellowship BACKGROUND: In DECAAF II, left atrial (LA) fibrosis ablation plus PVI did not improve AF outcome compared to PVI alone across the study cohort. We hy...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206671/ http://dx.doi.org/10.1093/europace/euad122.587 |
_version_ | 1785046282377625600 |
---|---|
author | Roney, C Alonso, J S L Sim, I Ulgen, O Rodero, C Strocchi, M Kotadia, I Honarbakhsh, S Narayan, S Plank, G Vigmond, E Williams, S E Niederer, S |
author_facet | Roney, C Alonso, J S L Sim, I Ulgen, O Rodero, C Strocchi, M Kotadia, I Honarbakhsh, S Narayan, S Plank, G Vigmond, E Williams, S E Niederer, S |
author_sort | Roney, C |
collection | PubMed |
description | FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Medical Research Council Fellowship BACKGROUND: In DECAAF II, left atrial (LA) fibrosis ablation plus PVI did not improve AF outcome compared to PVI alone across the study cohort. We hypothesize that biatrial fibrosis ablation could improve AF ablation therapy outcome in a subset of patients with properties identified through a large virtual in silico trial. PURPOSE: To investigate the effects of anatomy, fibrosis distribution, and LGE-MRI threshold on ablation outcome using a virtual cohort of 4000 patients. METHODS: We constructed 1000 biatrial models from a statistical shape model and we mapped pectinate muscles, Bachmann’s bundle and fibers from an atlas. For each of the 1000 anatomies we applied a randomly selected fibrosis map from a library of 100 clinical maps. We then created four versions of each case by assigning one of four randomly selected right atrial (RA) fibrosis distributions with Utah grades 1-4 (Fig 1A), giving 4000 virtual patients. Four ablation approaches were applied to each patient model after 5 seconds of AF: PVI, PVI & LA fibrosis, PVI & RA fibrosis, PVI & biatrial fibrosis. LGE-MRI was thresholded for fibrosis ablation at either 1.2 or 1.32 image intensity ratio (IIR). The outcome was classified 5 seconds post ablation. RESULTS: Biatrial fibrosis ablation is more effective than LA ablation. For patients with high (Utah 4) RA fibrosis, biatrial fibrosis ablation increases AF termination compared to LA fibrosis ablation (Figs 1B & 2A: 62% vs 14%), this compares to cases with low (Utah 1) RA fibrosis (21% vs 14%). For patients with high LA (Utah 4) fibrosis, biatrial ablation is more effective than LA ablation (Fig 2B: 52% vs 19%), this compares to patients with low (Utah 1) LA fibrosis (17% vs 7%). Increasing IIR threshold for ablation decreases termination (LA fibrosis ablation: 15.8% termination at IIR 1.2, 11.0% at IIR 1.32; biatrial: 41.5% at IIR1.2; 20.3% at IIR1.32). Anatomy has a larger effect on biatrial ablation outcome (31.2% of outcomes change between anatomies) than on PVI only ablation outcome (20.0% change). CONCLUSION: Biatrial fibrosis ablation is superior to LA fibrosis ablation for cases with high RA fibrosis. Biatrial fibrosis distribution should be considered when targeting AF ablation therapy. [Figure: see text] [Figure: see text] |
format | Online Article Text |
id | pubmed-10206671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-102066712023-05-25 In silico biatrial fibrosis ablation improves atrial fibrillation outcome Roney, C Alonso, J S L Sim, I Ulgen, O Rodero, C Strocchi, M Kotadia, I Honarbakhsh, S Narayan, S Plank, G Vigmond, E Williams, S E Niederer, S Europace 41.3.4 - Arrhythmias FUNDING ACKNOWLEDGEMENTS: Type of funding sources: Public grant(s) – National budget only. Main funding source(s): Medical Research Council Fellowship BACKGROUND: In DECAAF II, left atrial (LA) fibrosis ablation plus PVI did not improve AF outcome compared to PVI alone across the study cohort. We hypothesize that biatrial fibrosis ablation could improve AF ablation therapy outcome in a subset of patients with properties identified through a large virtual in silico trial. PURPOSE: To investigate the effects of anatomy, fibrosis distribution, and LGE-MRI threshold on ablation outcome using a virtual cohort of 4000 patients. METHODS: We constructed 1000 biatrial models from a statistical shape model and we mapped pectinate muscles, Bachmann’s bundle and fibers from an atlas. For each of the 1000 anatomies we applied a randomly selected fibrosis map from a library of 100 clinical maps. We then created four versions of each case by assigning one of four randomly selected right atrial (RA) fibrosis distributions with Utah grades 1-4 (Fig 1A), giving 4000 virtual patients. Four ablation approaches were applied to each patient model after 5 seconds of AF: PVI, PVI & LA fibrosis, PVI & RA fibrosis, PVI & biatrial fibrosis. LGE-MRI was thresholded for fibrosis ablation at either 1.2 or 1.32 image intensity ratio (IIR). The outcome was classified 5 seconds post ablation. RESULTS: Biatrial fibrosis ablation is more effective than LA ablation. For patients with high (Utah 4) RA fibrosis, biatrial fibrosis ablation increases AF termination compared to LA fibrosis ablation (Figs 1B & 2A: 62% vs 14%), this compares to cases with low (Utah 1) RA fibrosis (21% vs 14%). For patients with high LA (Utah 4) fibrosis, biatrial ablation is more effective than LA ablation (Fig 2B: 52% vs 19%), this compares to patients with low (Utah 1) LA fibrosis (17% vs 7%). Increasing IIR threshold for ablation decreases termination (LA fibrosis ablation: 15.8% termination at IIR 1.2, 11.0% at IIR 1.32; biatrial: 41.5% at IIR1.2; 20.3% at IIR1.32). Anatomy has a larger effect on biatrial ablation outcome (31.2% of outcomes change between anatomies) than on PVI only ablation outcome (20.0% change). CONCLUSION: Biatrial fibrosis ablation is superior to LA fibrosis ablation for cases with high RA fibrosis. Biatrial fibrosis distribution should be considered when targeting AF ablation therapy. [Figure: see text] [Figure: see text] Oxford University Press 2023-05-24 /pmc/articles/PMC10206671/ http://dx.doi.org/10.1093/europace/euad122.587 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | 41.3.4 - Arrhythmias Roney, C Alonso, J S L Sim, I Ulgen, O Rodero, C Strocchi, M Kotadia, I Honarbakhsh, S Narayan, S Plank, G Vigmond, E Williams, S E Niederer, S In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title | In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title_full | In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title_fullStr | In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title_full_unstemmed | In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title_short | In silico biatrial fibrosis ablation improves atrial fibrillation outcome |
title_sort | in silico biatrial fibrosis ablation improves atrial fibrillation outcome |
topic | 41.3.4 - Arrhythmias |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10206671/ http://dx.doi.org/10.1093/europace/euad122.587 |
work_keys_str_mv | AT roneyc insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT alonsojsl insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT simi insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT ulgeno insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT roderoc insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT strocchim insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT kotadiai insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT honarbakhshs insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT narayans insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT plankg insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT vigmonde insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT williamsse insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome AT niederers insilicobiatrialfibrosisablationimprovesatrialfibrillationoutcome |